Gilead Sciences (GILD) Total Current Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Total Current Liabilities for 18 consecutive years, with $9.5 billion the latest figure, recorded in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $9.5 billion, down 23.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 billion (down 23.23% YoY), and the FY2025 annual result was $11.8 billion, down 1.59% from the prior year.
• Total Current Liabilities was $9.5 billion for Q1 2026 at Gilead Sciences, down from $11.8 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $14.0 billion in Q2 2023 and troughed at $8.6 billion in Q1 2022.
• Average Total Current Liabilities over 5 years is $11.3 billion, with a median of $11.3 billion recorded in 2023.
• Year-over-year, Total Current Liabilities soared 51.45% in 2023 and decreased 23.23% in 2026.
• Over 5 years, Total Current Liabilities stood at $11.2 billion in 2022, then increased by 0.38% to $11.3 billion in 2023, then increased by 6.42% to $12.0 billion in 2024, then slipped by 1.59% to $11.8 billion in 2025, then declined by 19.78% to $9.5 billion in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $9.5 billion in Q1 2026, $11.8 billion in Q4 2025, and $12.3 billion in Q3 2025.